Despite challenging conditions posed by the COVID-19 outbreak, the DRIVE project successfully tested how well various brands of flu vaccines worked across five European countries and a range of age groups.

CLCI, together with MEP Tomislav Sokol and the European Institute for Innovation through Health Data, has produced a report exploring ways of improving the use of data in national immunisation programme planning.

The efficacy of the BNT162b2 vaccine in pediatrics was assessed by randomised trials before the Omicron variant’s emergence.

The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.

Do not miss the opportunity to listen to this enthusiastic and insightful conversation between Debby van Riel, Carolien van de Sandt and Jenna Guthmiller

In an epidemiological update, the ECDC urges EU/EEA Member States to strengthen vaccination campaigns and prepare for the possible need to increase emergency department and ICU capacity

Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults.

Previous comparative analyses of people admitted to hospital for COVID-19 versus influenza evaluated the risk of death, hospital readmission, and a narrow set of health outcomes up to 6 months following infection.

The NIRSE-GAL study shows in real time the evolution of the coverage achieved by immunisation with Nirsevimab in children and compares RSV admissions in different population groups of children and adults in Galicia in Spain with previous years.

Since 2018, the work of the European Commission on vaccination has been guided by the Council Recommendation on strengthened cooperation against vaccine-preventable diseases. The aim of this report is to support possible policy developments in the future.

Influenza is not a single virus, but a collection of subtypes broken down into many different strains.

Protecting infants from RSV with new tools: vaccines for pregnant women and use of monoclonal antibodies have been approved for use in the European Union to prevent RSV among young children. Are those tools working?